Pharma Pulse 7/15/25: Walgreens’ Clinical Trials Journey; Strategies in Today’s Market for Pricing and Reimbursement Models

Walgreens’ Clinical Trials Journey: Three Years In

In an interview with Applied Clinical Trials, Ramita Tandon, chief biopharma officer, Walgreens, reflected on the company’s three-year clinical trials journey, emphasizing its community-based, pharmacy-led approach to expanding access and inclusivity in research through strategic partnerships, patient-centered design, and innovative models that reach millions nationwide.

Strategies in Today’s Market for Pricing and Reimbursement Models

In a Pharmaceutical Executive peer exchange, panelists discussed how today’s market is opening to innovative pricing and reimbursement models—provided manufacturers align closely with payer priorities, offer clear value propositions, and design outcome-based contracts that integrate with existing data systems while sharing financial risk.

Is There a Marketplace for Mail Order?

Despite uncertainties around regulation and definitions, mail order and home delivery pharmacy models are rapidly expanding beyond traditional boundaries—driven by profitability, patient demand, and evolving care delivery models—while new state laws, such as Arkansas’ pharmacy benefit management ban, could reshape who controls this growing channel and how care is delivered in the future.

Mayo Clinic Researchers Link CAR-T Cell Aging to Cancer Relapse

Mayo Clinic researchers have identified premature aging—or senescence—of CAR-T cells as a key driver of cancer relapse, revealing that the way these immune cells are engineered can influence their longevity and effectiveness, a discovery that may shape the next generation of more durable, personalized CAR-T therapies.

Takeda’s Narcolepsy Blockbuster Hopeful Secures Double Phase III Wins, Teeing up FDA Filing

Takeda is preparing to file for FDA approval of its potential blockbuster narcolepsy drug oveporexton after it met all primary and secondary endpoints in two phase III trials, demonstrating significant improvements in excessive daytime sleepiness and other key symptoms, with no serious treatment-related adverse events reported.